Renal denervation in patients with resistant hypertension significantly reduced mean daytime systolic blood pressure by 17.3 mmHg at 12 months (p < 0.01).
Observational (n=33)
No
Does renal denervation reduce ambulatory blood pressure in patients with resistant hypertension?
In a real-world setting, renal denervation provided sustained and clinically meaningful reductions in ambulatory blood pressure at 12 months in patients with resistant hypertension.
Mean Difference: -17.3
valor p: p=< 0.01
Objective: Renal denervation (RDN) has re-emerged as an adjunctive therapeutic option for selected patients with resistant hypertension (HTN) despite optimized medical therapy. This study aimed to characterize the baseline clinical profile of patients undergoing RDN and to evaluate changes in ambulatory blood pressure (BP) parameters during follow-up in a real-world setting. Design and method: This was a single-center observational study including 33 patients with resistant HTN treated with RDN. Ambulatory BP monitoring was performed at baseline and repeated at 6 and 12 months. Continuous variables are presented as mean ± standard deviation and categorical variables as percentages. Results: The mean age of the cohort was 62 ± 9 years, and 67% of patients were male. Cardiovascular risk factors were highly prevalent, including dyslipidemia (91%) and diabetes mellitus (42%), with 36% of those requiring insulin therapy. At baseline, mean 24-hour SBP was 152.5 ± 16.3 mmHg, diastolic blood pressure (DBP) 87.8 ± 16.5 mmHg, and heart rate 69.5 ± 11.8 beats per minute. The mean number of ablations per procedure was 27.5 ± 9.5. At 12 months, mean daytime SBP decreased from 157.9 ± 15.6 mmHg to 140.6 ± 17.9 mmHg (-17.3 ± 10.1 mmHg; p < 0.01), while nighttime SBP decreased from 140.6 ± 20.3 mmHg to 125.5 ± 19.2 mmHg (-15.1 ± 9.8 mmHg; p < 0.01). Daytime and nighttime DBP also showed significant reductions (-8.1 mmHg and -5.5 mmHg, respectively). Overall, 81.5% of patients met the criteria for response at 12 months. No major periprocedural complications were observed, and renal function and electrolyte levels remained stable throughout follow-up. Conclusions: In this real-world cohort of patients with resistant HTN, RDN was associated with a sustained and clinically meaningful reduction in ambulatory BP at 12 months, with most patients classified as responders. These findings support RDN as a safe and effective adjunctive treatment option for patients with long-standing resistant HTN inadequately controlled with pharmacological therapy.
Batista et al. (Fri,) conducted a observational in Resistant hypertension (n=33). Renal denervation was evaluated on Change in mean daytime systolic blood pressure at 12 months (MD -17.3, p=< 0.01). Renal denervation in patients with resistant hypertension significantly reduced mean daytime systolic blood pressure by 17.3 mmHg at 12 months (p < 0.01).